Search Results - "HEERA, Jayvant"

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients by Gulick, Roy M, Fatkenheuer, Gerd, Burnside, Robert, Hardy, W David, Nelson, Mark R, Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon, Heera, Jayvant R

“…Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we…”
Get full text

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies by MCGOVERN, Rachel A, THIELEN, Alexander, HARRIGAN, P. Richard, MO, Theresa, WINNIE DONG, WOODS, Conan K, CHAPMAN, Douglass, LEWIS, Marilyn, JAMES, Ian, HEERA, Jayvant, VAIDEZ, Hernan

“…The MOTIVATE-1 and 2 studies compared maraviroc (MVC) along with optimized background therapy (OBT) vs. placebo along with OBT in treatment-experienced…”
Get full text

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients by Funderburg, Nicholas, Kalinowska, Magdalena, Eason, James, Goodrich, James, Heera, Jayvant, Mayer, Howard, Rajicic, Natasa, Valdez, Hernan, Lederman, Michael M

“…Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated…”
Get full text

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects by Vourvahis, Manoli, McFadyen, Lynn, Nepal, Sunil, Valluri, Srinivas Rao, Fang, Annie, Fate, Gwendolyn D., Wood, Linda S., Marshall, Jean‐Claude, Chan, Phylinda L. S., Nedderman, Angus, Haynes, Julian, Savage, Mark E., Clark, Andrew, Smith, Kimberly Y., Heera, Jayvant

“…Maraviroc is a C‐C chemokine receptor type‐5 antagonist approved for the treatment of HIV‐1. Previous studies show that cytochrome P450 3A5 (CYP3A5) plays a…”
Get full text

Pharmacokinetic Interaction between Maraviroc and Fosamprenavir-Ritonavir: an Open-Label, Fixed-Sequence Study in Healthy Subjects by VOURVAHIS, Manoli, PLOTKA, Anna, DA COSTA, Laure Mendes, FANG, Annie, HEERA, Jayvant

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial by McGovern, Rachel A, Thielen, Alexander, Portsmouth, Simon, Mo, Theresa, Dong, Winnie, Woods, Conan K, Zhong, Xiaoyin, Brumme, Chanson J, Chapman, Douglass, Lewis, Marilyn, James, Ian, Heera, Jayvant, Valdez, Hernan, Harrigan, P Richard

“…BACKGROUND:MERIT was a randomized trial comparing maraviroc (MVC) + Combivir versus efavirenz (EFV) + Combivir in drug-naive patients screened as having R5…”
Get full text

Use of Cellular HIV DNA to Predict Virologic Response to Maraviroc: Performance of Population-Based and Deep Sequencing by Swenson, Luke C., Dong, Winnie W. Y., Mo, Theresa, Demarest, James, Chapman, Doug, Ellery, Suzanne, Heera, Jayvant, Valdez, Hernan, Poon, Art F. Y., Harrigan, P. Richard

“…Background. A tropism test is required before administration of the antiretroviral drug maraviroc. However, plasma RNA testing is not possible in patients with…”
Get full text

Genotypic Analysis of the V3 Region of HIV from Virologic Nonresponders to Maraviroc-Containing Regimens Reveals Distinct Patterns of Failure by SWENSON, Luke C, CHUI, Celia K. S, JAMES, Ian, PORTSMOUTH, Simon, GOODRICH, James, HEERA, Jayvant, VALDEZ, Hernan, HARRIGAN, P. Richard, BRUMME, Chanson J, CHAN, Dennison, WOODS, Conan K, MO, Theresa, DONG, Winnie, CHAPMAN, Doug, LEWIS, Marilyn, DEMAREST, James F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia by Madhi, Shabir A, Heera, Jayvant R, Kuwanda, Locadiah, Klugman, Keith P

“…Pneumonia remains the leading cause of death in young children. The poor specificity of chest radiographs (CXRs) to diagnose pneumococcal pneumonia may…”
Get full text

Gamma Interferon Production in Response to Mycobacterium bovis BCG and Mycobacterium tuberculosis Antigens in Infants Born to Human Immunodeficiency Virus-Infected Mothers by Van Rie, Annelies, Madhi, Shabir A, Heera, Jayvant R, Meddows-Taylor, Stephen, Wendelboe, Aaron M, Anthony, Fiona, Violari, Avy, Tiemessen, Caroline T

“…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN by Heera, Jayvant, Valluri, Srinivas, Craig, Charles, Fang, Annie, Thomas, Neal, Dan Meyer, Ralph, Demarest, James

“…Introduction MODERN (A4001095) was the first prospective phase 3 study comparing genotype vs phenotype (Trofile™) tropism assessments. Materials and Methods…”
Get full text

Clinical relevance of CYP3A5 genotype on maraviroc exposures by Vourvahis, Manoli, McFadyen, Lynn, Heera, Jayvant, Clark, Andrew

Get full text

The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers by Vourvahis, Manoli, Plotka, Anna, Kantaridis, Constantino, Fang, Annie, Heera, Jayvant

“…To evaluate the effects of boceprevir (BOC) and telaprevir (TVR) on the pharmacokinetics (PK) of maraviroc (MVC) in healthy volunteers. In this open-label,…”
Get full text

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection by Cooper, David A., Heera, Jayvant, Heera, Jayvant, Goodrich, James, Tawadrous, Margaret, Saag, Michael, DeJesus, Edwin, Clumeck, Nathan, Walmsley, Sharon, Ting, Naitee, Coakley, Eoin, Reeves, Jacqueline D., Reyes-Teran, Gustavo, Westby, Mike, Van Der Ryst, Elna, Ive, Prudence, Mohapi, Lerato, Mingrone, Horacio, Horban, Andrzej, Hackman, Frances, Sullivan, John, Mayer, Howard

“…Background. The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in…”
Get full text

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment by Stellbrink, Hans-Jürgen, Le Fevre, Eric, Carr, Andrew, Saag, Michael S, Mukwaya, Geoffrey, Nozza, Silvia, Valluri, Srinivas Rao, Vourvahis, Manoli, Rinehart, Alex R, McFadyen, Lynn, Fichtenbaum, Carl, Clark, Andrew, Craig, Charles, Fang, Annie F, Heera, Jayvant

“…OBJECTIVE:The aim of this study was to evaluate the efficacy of maraviroc along with darunavir/ritonavir, all once daily, for the treatment of…”
Get full text

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 by HARDY, W. David, GULICK, Roy M, MAYER, Howard, FÄTKENHEUER, Gerd, NELSON, Mark, HEERA, Jayvant, RAJICIC, Natasa, GOODRICH, James

“…Maraviroc, the first approved CCR5 antagonist, demonstrated 48-week safety and virologic efficacy in CCR5-tropic HIV-infected, treatment-experienced patients;…”
Get full text

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1 by Giaquinto, Carlo, Mawela, Muthuhadini Patience, Chokephaibulkit, Kulkanya, Negra, Marinella Della, Mitha, Ismail Haroon, Fourie, Jan, Fang, Annie, van der Ryst, Elna, Valluri, Srinivas Rao, Vourvahis, Manoli, Zhang-Roper, Rebecca Yanhui, Craig, Charles, McFadyen, Lynn, Clark, Andrew, Heera, Jayvant

“…BACKGROUND:Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031…”
Get full text

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings by COOPER, David A, HEERA, Jayvant, SAAG, Michael, VAN DER RYST, Elna, IVE, Prudence, BOTES, Mariette, DEJESUS, Edwin, BURNSIDE, Robert, CLUMECK, Nathan, WALMSLEY, Sharon, LAZZARIN, Adriano, MUKWAYA, Geoffrey

“…Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with…”
Get full text

Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay by van der Ryst, Elna, Heera, Jayvant, Demarest, James, Knirsch, Charles

“…Assays to identify infectious organisms are critical for diagnosis and enabling the development of therapeutic agents. The demonstration that individuals with…”
Get full text

Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients by Swenson, Luke C., Mo, Theresa, Dong, Winnie W.Y., Zhong, Xiaoyin, Woods, Conan K., Jensen, Mark A., Thielen, Alexander, Chapman, Douglass, Lewis, Marilyn, James, Ian, Heera, Jayvant, Valdez, Hernan, Harrigan, P. Richard

“…Background. The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus…”
Get full text